Pulmonary fibrosis characterizes a heterogeneous group of incurable lung disorders with progressive, irreversible destruction of the lung architecture and disruption of gas exchange. The prototype of these diseases, idiopathic pulmonary fibrosis (IPF), has a median life expectancy of three years from diagnosis to death. Currently, no effective treatment is available for this disease. The first clue as to the molecular mechanism responsible for IPF emerged from the discovery by two groups, including our group, that a subset of pulmonary fibrosis is caused by mutations in the genes encoding the protein component (TERT) and the RNA component (TERC) of telomerase, a ribonucleoprotein enzyme that catalyzes the addition of hexameric nucleotide repeats to the ends of linear chromosomes. In our studies, all affected members with mutations in telomerase have evidence of shortened telomere lengths in circulating leukocytes. However, mutations in these genes comprise less than 15% of patients with the familial form of the disease and less than 3% of patients with the more common sporadic form of the disease. Here we will characterize the genetic etiology of pulmonary fibrosis in a large collection of familial and sporadic pulmonary fibrosis subjects. First, we will determine if telomere dysfunction and telomere shortening is a more generalized feature of familial and sporadic pulmonary fibrosis in subjects who do not have telomerase mutations, as our preliminary studies suggest. Second, we will determine if mutations in other genes involved in telomere maintenance contribute to PF in the subset of patients without coding mutations in telomerase. Third, we will map new genetic loci that cause pulmonary fibrosis in large kindreds where the disease fails to co-segregate with the genes known to cause lung scarring. These studies have the potential for breaking new conceptual grounds for determining the underlying molecular pathogenesis of pulmonary fibrosis. Our multi-pronged approaches offer the promise of providing new targets for therapeutic intervention for this lethal, age-associated lung disease.
Idiopathic pulmonary fibrosis (IPF) is the prototype of a group of lethal diseases characterized by progressive, irreversible, lung scarring. A recent clue as to the genetic underpinnings of this disorder came from our finding that mutations in the genes encoding telomerase cause the disease in a subset of families with autosomal dominant pulmonary fibrosis. In this grant we will investigate the link between telomerase dysfunction and pulmonary fibrosis through an integrated, clinical and genetic approach to patients and their families with this devastating disorder.
|Xing, Chao; Garcia, Christine Kim (2016) Epigenetic inheritance of telomere length obscures identification of causative PARN locus. J Med Genet 53:356-8|
|Stuart, Bridget D; Choi, Jungmin; Zaidi, Samir et al. (2015) Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet 47:512-7|
|Tokman, Sofya; Singer, Jonathan P; Devine, Megan S et al. (2015) Clinical outcomes of lung transplant recipients with telomerase mutations. J Heart Lung Transplant 34:1318-24|
|Garcia, Christine Kim (2015) Running short on time: lung transplant evaluation for telomere-related pulmonary fibrosis. Chest 147:1450-2|
|Stuart, Bridget D; Lee, Joyce S; Kozlitina, Julia et al. (2014) Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2:557-65|
|Maitra, Meenakshi; Dey, Moushumi; Yuan, Wen-Cheng et al. (2013) Lung fibrosis-associated surfactant protein A1 and C variants induce latent transforming growth factor Î²1 secretion in lung epithelial cells. J Biol Chem 288:27159-71|
|Kozlitina, Julia; Garcia, Christine Kim (2012) Red blood cell size is inversely associated with leukocyte telomere length in a large multi-ethnic population. PLoS One 7:e51046|
|Chambers, Daniel Charles; Clarke, Belinda Edith; McGaughran, Julie et al. (2012) Lung fibrosis, premature graying, and macrocytosis. Am J Respir Crit Care Med 186:e8-9|
|Vece, Timothy J; Schecter, Marc G; Gatti, Richard A et al. (2012) Rapid and progressive pulmonary fibrosis in 2 families with DNA repair deficiencies of undetermined etiology. J Pediatr 160:700-702.e3|
|Maitra, Meenakshi; Cano, Christopher A; Garcia, Christine Kim (2012) Mutant surfactant A2 proteins associated with familial pulmonary fibrosis and lung cancer induce TGF-Î²1 secretion. Proc Natl Acad Sci U S A 109:21064-9|
Showing the most recent 10 out of 16 publications